Charles River Laboratories International, Inc. (NYSE: CRL), a Wilmington, Massachusetts-based provider of essential products and services to accelerate research and drug development efforts, acquired Oncotest GmbH, a Freiburg, Germany-based contract research organization (CRO) providing discovery services for oncology, for approximately €34m.
The purchase price is subject to post-closing adjustments. In addition to the initial price, the transaction includes a potential additional payment of €2m based on future performance.
Oncotest offers an integrated portfolio of target discovery and validation services for preclinical oncology researchers. The company specializes in in vivo pharmacology services, leveraging a collection of more than 400 patient-derived xenograft (PDX) tumor models, as well as a full range of in vitro assays using both commercially available and proprietary PDX-derived cell lines.
Oncotest has become part of Charles River’s In Vivo Discovery business, which is reported in the Discovery and Safety Assessment segment. Integrated with Charles River’s portfolio of human xenografts, syngeneic, and humanized immunotherapy research models, flow cytometry, and IVIS® imaging services, the acquisition aims to create a premier oncology portfolio for the validation of novel cancer therapies.